Precision Digital Health Appoints Connie Pearcy as Chief Executive Officer

Why It Matters

The leadership change equips PDH with proven scaling expertise as it seeks to broaden its wearable‑data SaaS offering, positioning the company to capture growing demand for real‑time patient monitoring in clinical trials.

Key Takeaways

• Connie Pearcy named CEO of Precision Digital Health.
• Pearcy previously grew CREO’s tech services 55% YoY, leading to PE exit.
• PDH focuses on wearable data integration for cardiometabolic trials.
• Leadership shift aims to scale SaaS platform SUMMA globally.

Pulse Analysis

The clinical‑trial landscape is rapidly evolving as sponsors turn to continuous, real‑time patient monitoring to improve data quality and reduce study timelines. Wearable glucose monitors, blood‑pressure cuffs, and activity trackers now generate massive streams of patient‑generated health data, creating a niche for specialized integration platforms. Precision Digital Health’s SUMMA SaaS solution aggregates these signals, normalizes them, and feeds them into hybrid trial designs and real‑world evidence studies. As pharmaceutical companies accelerate enrollment in cardiometabolic programs, the demand for seamless, regulatory‑compliant data pipelines has surged, positioning PDH as a critical enabler of next‑generation trial execution.

Connie Pearcy brings a decade of operational leadership from CREO, where she expanded the technology services division into the firm’s primary revenue engine, delivering roughly 55 % year‑over‑year growth and culminating in a private‑equity exit in 2023. Her track record of scaling high‑growth health‑tech platforms aligns with PDH’s ambition to broaden its global footprint and support an expanding roster of sponsors. By overseeing product development, sales, and finance, Pearcy is expected to tighten execution, drive margin improvement, and accelerate the rollout of new wearable integrations across the SUMMA ecosystem.

The appointment underscores PDH’s strategic push to capture a larger share of the $10 billion wearable‑data market projected for clinical research by 2028. With Thomas Wells shifting to a product‑focused role, the company can double‑down on innovation while maintaining strong client relationships and regulatory oversight. Competitors such as Medable and Science 37 are also expanding, but PDH’s deep expertise in cardiometabolic devices and its end‑to‑end service model provide a differentiated value proposition. Investors and partners will watch closely as the new leadership team translates operational rigor into sustained revenue growth and market leadership.